Literature DB >> 10411591

S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions.

A I Galán1, M E Muñoz, R Jiménez.   

Abstract

We studied the effect of cyclosporin A (CyA) on liver plasma membrane (LPM) composition, fluidity, and functions and on hepatic glutathione (GS) and oxidative status. We also evaluated the ability of S-adenosylmethionine (SAMe) to antagonize the CyA-induced disturbances in rats. The animals were randomly divided into four groups and treated daily with saline, CyA vehicle, CyA, and SAMe plus CyA, respectively, for 1 week. Bile, blood, and liver samples and LPM vesicles were obtained at the end of the treatments. CyA-induced cholestasis was associated with alterations in LPM composition and fluidity. The contents of total phospholipids, phosphatidylcholine, and proteins were decreased and cholesterol and the cholesterol/phospholipid molar ratio increased. Na(+), K(+)-ATPase activity was decreased, whereas those of 5'-nucleotidase, Mg(2+)-ATPase, and gamma-glutamyltransferase increased. The hepatic contents of proteins and GS and the reduced/oxidized glutathione molar ratio were decreased and hepatic malondialdehyde increased. SAMe cotreatment 1) significantly improved or abolished the CyA-induced changes in LPM fluidity and composition and the changes in the activity of the carrier and enzymes tested, 2) counteracted the hepatic depletion of GS and proteins caused by CyA and normalized the reduced/oxidized glutathione ratio, and, as expected, 3) prevented cholestasis and the inhibitory effect of CyA on hepatobiliary transport of the major bile components. We conclude that CyA-induced cholestasis and hepatotoxicity in the rat is associated with changes in LPM composition and fluidity, liver GS depletion, and oxidative stress. SAMe cotreatment significantly improves or totally protects against these hepatotoxic effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411591

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells.

Authors:  H Motohashi; T Katsura; H Saito; K Inui
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  Prenatal alcohol-induced neuroapoptosis in rat brain cerebral cortex: protective effect of folic acid and betaine.

Authors:  Ibrahim Sogut; Onur Uysal; Aysegul Oglakci; Ferruh Yucel; Kazim Kartkaya; Gungor Kanbak
Journal:  Childs Nerv Syst       Date:  2017-01-06       Impact factor: 1.475

3.  Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment.

Authors:  A I Galán; M E Muñoz; J Palomero; C Moreno; R Jiménez
Journal:  J Physiol Biochem       Date:  2000-09       Impact factor: 4.158

4.  Reversing gastric mucosal alterations during ethanol-induced chronic gastritis in rats by oral administration of Opuntia ficus-indica mucilage.

Authors:  Ricardo Vázquez-Ramírez; Marisela Olguín-Martínez; Carlos Kubli-Garfias; Rolando Hernández-Muñoz
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

5.  Changes in lipid composition in hippocampus early and late after status epilepticus induced by kainic acid in wistar rats.

Authors:  Felipe Dal-Pizzol; João Quevedo; Emílio Streck; Roger Walz; José Cláudio F Moreira
Journal:  Metab Brain Dis       Date:  2007-03       Impact factor: 3.584

6.  Biliary diseases in heart transplanted patients: a comparison between cyclosporine A versus tacrolimus-based immunosuppression.

Authors:  J Stief; H U Stempfle; M Götzberger; P Uberfuhr; M Köpple; P Lehnert; C Kaiser; Uwe Schiemann
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

7.  Oxidative Stress and Liver Morphology in Experimental Cyclosporine A-Induced Hepatotoxicity.

Authors:  Agnieszka Korolczuk; Kinga Caban; Magdalena Amarowicz; Grażyna Czechowska; Joanna Irla-Miduch
Journal:  Biomed Res Int       Date:  2016-05-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.